chromophobe renal cell carcinoma (Cancer)
Information
- Disease name
- chromophobe renal cell carcinoma
- Disease ID
- DOID:4471
- Description
- "A renal cell carcinoma that has_material_basis_in chromophobe cell that appear pale when viewed under microscope, but that are larger and display different features than clear cells." [url:http\://www.cancer.org/acs/groups/cid/documents/webcontent/003107-pdf.pdf, url:https\://rarediseases.info.nih.gov/diseases/6064/chromophobe-renal-cell-carcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03635892 | Active, not recruiting | Phase 2 | A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | August 13, 2018 | August 2024 |
| NCT01767636 | Active, not recruiting | Phase 2 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | May 16, 2013 | November 16, 2024 |
| NCT03541902 | Active, not recruiting | Phase 2 | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | May 15, 2018 | July 31, 2025 |
| NCT00126503 | Completed | Phase 1/Phase 2 | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | May 2005 | February 2012 |
| NCT06339138 | Recruiting | Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study | February 20, 2018 | January 31, 2027 | |
| NCT04413123 | Recruiting | Phase 2 | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | November 5, 2020 | December 20, 2025 |
| NCT04623502 | Recruiting | N/A | An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | September 30, 2019 | September 30, 2026 |
| NCT03866382 | Recruiting | Phase 2 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | May 13, 2019 | February 28, 2025 |
| NCT04071223 | Recruiting | Phase 2 | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study | July 29, 2020 | October 1, 2024 |
| NCT03685448 | Unknown status | Phase 2 | ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) | April 11, 2019 | April 30, 2024 |
| NCT03177239 | Unknown status | Phase 2 | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) | October 19, 2017 | December 31, 2022 |
- Disase is a (Disease Ontology)
- DOID:4450
- Cross Reference ID (Disease Ontology)
- GARD:6064
- Cross Reference ID (Disease Ontology)
- MESH:D002292
- Cross Reference ID (Disease Ontology)
- NCI:C4146
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:128667008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1266042
- Exact Synonym (Disease Ontology)
- chromophobe adenocarcinoma
- Exact Synonym (Disease Ontology)
- Chromophobe carcinoma of kidney
- Exact Synonym (Disease Ontology)
- kidney chromophobe
- Exact Synonym (Disease Ontology)
- renal cell carcinoma, chromophobe cell
- OrphaNumber from OrphaNet (Orphanet)
- 319303